In a recent analysis of HRSA data, the American Hospital Association has turned the tables on drug companies and accused them of being far more likely to violate 340B Drug Pricing Program rules. In ...
Senate Health, Education, Labor, and Pensions Committee Chairman Bill Cassidy (R-Louisiana) recently released the results of an investigation into the 340B Drug Pricing Program. Here are four key ...
New approach methodologies (NAMs) – such as organoids, spheroids and microfluidic chip systems – aim to streamline early-stage drug discovery and revolutionize preclinical testing by augmenting ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results